402 related articles for article (PubMed ID: 30587297)
1. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.
Commons RJ; Simpson JA; Thriemer K; Hossain MS; Douglas NM; Humphreys GS; Sibley CH; Guerin PJ; Price RN
Lancet Infect Dis; 2019 Jan; 19(1):91-101. PubMed ID: 30587297
[TBL] [Abstract][Full Text] [Related]
2. The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network.
Hossain MS; Commons RJ; Douglas NM; Thriemer K; Alemayehu BH; Amaratunga C; Anvikar AR; Ashley EA; Asih PBS; Carrara VI; Lon C; D'Alessandro U; Davis TME; Dondorp AM; Edstein MD; Fairhurst RM; Ferreira MU; Hwang J; Janssens B; Karunajeewa H; Kiechel JR; Ladeia-Andrade S; Laman M; Mayxay M; McGready R; Moore BR; Mueller I; Newton PN; Thuy-Nhien NT; Noedl H; Nosten F; Phyo AP; Poespoprodjo JR; Saunders DL; Smithuis F; Spring MD; Stepniewska K; Suon S; Suputtamongkol Y; Syafruddin D; Tran HT; Valecha N; Van Herp M; Van Vugt M; White NJ; Guerin PJ; Simpson JA; Price RN
PLoS Med; 2020 Nov; 17(11):e1003393. PubMed ID: 33211712
[TBL] [Abstract][Full Text] [Related]
3. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
van der Pluijm RW; Tripura R; Hoglund RM; Pyae Phyo A; Lek D; Ul Islam A; Anvikar AR; Satpathi P; Satpathi S; Behera PK; Tripura A; Baidya S; Onyamboko M; Chau NH; Sovann Y; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Chutasmit K; Saelow C; Runcharern R; Kaewmok W; Hoa NT; Thanh NV; Hanboonkunupakarn B; Callery JJ; Mohanty AK; Heaton J; Thant M; Gantait K; Ghosh T; Amato R; Pearson RD; Jacob CG; Gonçalves S; Mukaka M; Waithira N; Woodrow CJ; Grobusch MP; van Vugt M; Fairhurst RM; Cheah PY; Peto TJ; von Seidlein L; Dhorda M; Maude RJ; Winterberg M; Thuy-Nhien NT; Kwiatkowski DP; Imwong M; Jittamala P; Lin K; Hlaing TM; Chotivanich K; Huy R; Fanello C; Ashley E; Mayxay M; Newton PN; Hien TT; Valecha N; Smithuis F; Pukrittayakamee S; Faiz A; Miotto O; Tarning J; Day NPJ; White NJ; Dondorp AM;
Lancet; 2020 Apr; 395(10233):1345-1360. PubMed ID: 32171078
[TBL] [Abstract][Full Text] [Related]
4. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.
Thriemer K; Degaga TS; Christian M; Alam MS; Rajasekhar M; Ley B; Hossain MS; Kibria MG; Tego TT; Abate DT; Weston S; Mnjala H; Rumaseb A; Satyagraha AW; Sadhewa A; Panggalo LV; Ekawati LL; Lee G; Anose RT; Kiros FG; Simpson JA; Karahalios A; Woyessa A; Baird JK; Sutanto I; Hailu A; Price RN
Lancet; 2023 Dec; 402(10417):2101-2110. PubMed ID: 37979594
[TBL] [Abstract][Full Text] [Related]
5. UK malaria treatment guidelines 2016.
Lalloo DG; Shingadia D; Bell DJ; Beeching NJ; Whitty CJM; Chiodini PL;
J Infect; 2016 Jun; 72(6):635-649. PubMed ID: 26880088
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Smithuis F; Kyaw MK; Phe O; Win T; Aung PP; Oo AP; Naing AL; Nyo MY; Myint NZ; Imwong M; Ashley E; Lee SJ; White NJ
Lancet Infect Dis; 2010 Oct; 10(10):673-81. PubMed ID: 20832366
[TBL] [Abstract][Full Text] [Related]
7. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M; van der Pluijm RW; Weya J; Njuguna P; Ngama M; Kalume P; Mwambingu G; Ngetsa C; Wambua J; Boga M; Mturi N; Lal AA; Khuroo A; Taylor WRJ; Gonçalves S; Miotto O; Dhorda M; Mutinda B; Mukaka M; Waithira N; Hoglund RM; Imwong M; Tarning J; Day NPJ; White NJ; Bejon P; Dondorp AM
Lancet Infect Dis; 2021 Oct; 21(10):1395-1406. PubMed ID: 34111412
[TBL] [Abstract][Full Text] [Related]
8. Artemisinin-based combination therapy for treating uncomplicated malaria.
Sinclair D; Zani B; Donegan S; Olliaro P; Garner P
Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD007483. PubMed ID: 19588433
[TBL] [Abstract][Full Text] [Related]
9. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.
Zani B; Gathu M; Donegan S; Olliaro PL; Sinclair D
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD010927. PubMed ID: 24443033
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.
Commons RJ; Rajasekhar M; Edler P; Abreha T; Awab GR; Baird JK; Barber BE; Chu CS; Cui L; Daher A; Gonzalez-Ceron L; Grigg MJ; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Lidia K; Llanos-Cuentas A; Longley RJ; Pereira DB; Pasaribu AP; Pukrittayakamee S; Rijal KR; Sutanto I; Taylor WRJ; Thanh PV; Thriemer K; Vieira JLF; Watson JA; Zuluaga-Idarraga LM; White NJ; Guerin PJ; Simpson JA; Price RN;
Lancet Infect Dis; 2024 Feb; 24(2):172-183. PubMed ID: 37748496
[TBL] [Abstract][Full Text] [Related]
12. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.
Gogtay N; Kannan S; Thatte UM; Olliaro PL; Sinclair D
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD008492. PubMed ID: 24163021
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border.
Saito M; Carrara VI; Gilder ME; Min AM; Tun NW; Pimanpanarak M; Viladpai-Nguen J; Paw MK; Haohankhunnatham W; Konghahong K; Phyo AP; Chu C; Turner C; Lee SJ; Duanguppama J; Imwong M; Bancone G; Proux S; Singhasivanon P; White NJ; Nosten F; McGready R
BMC Med; 2021 Jun; 19(1):132. PubMed ID: 34107963
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.
Phong NC; Chavchich M; Quang HH; San NN; Birrell GW; Chuang I; Martin NJ; Manh ND; Edstein MD
Malar J; 2019 Jan; 18(1):10. PubMed ID: 30654808
[TBL] [Abstract][Full Text] [Related]
15. The high risk of malarial recurrence in patients with Plasmodium-mixed infection after treatment with antimalarial drugs: a systematic review and meta-analysis.
Mahittikorn A; Masangkay FR; Kotepui KU; Milanez GJ; Kotepui M
Parasit Vectors; 2021 May; 14(1):280. PubMed ID: 34034802
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea.
Tavul L; Hetzel MW; Teliki A; Walsh D; Kiniboro B; Rare L; Pulford J; Siba PM; Karl S; Makita L; Robinson L; Kattenberg JH; Laman M; Oswyn G; Mueller I
Malar J; 2018 Oct; 17(1):350. PubMed ID: 30290825
[TBL] [Abstract][Full Text] [Related]
17. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.
Ratcliff A; Siswantoro H; Kenangalem E; Maristela R; Wuwung RM; Laihad F; Ebsworth EP; Anstey NM; Tjitra E; Price RN
Lancet; 2007 Mar; 369(9563):757-765. PubMed ID: 17336652
[TBL] [Abstract][Full Text] [Related]
18. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
Rajasekhar M; Simpson JA; Ley B; Edler P; Chu CS; Abreha T; Awab GR; Baird JK; Bancone G; Barber BE; Grigg MJ; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Llanos-Cuentas A; Pukrittayakamee S; Rijal KR; Saravu K; Sutanto I; Taylor WRJ; Thriemer K; Watson JA; Guerin PJ; White NJ; Price RN; Commons RJ;
Lancet Infect Dis; 2024 Feb; 24(2):184-195. PubMed ID: 37748497
[TBL] [Abstract][Full Text] [Related]
19. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
[TBL] [Abstract][Full Text] [Related]
20. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.
van der Pluijm RW; Imwong M; Chau NH; Hoa NT; Thuy-Nhien NT; Thanh NV; Jittamala P; Hanboonkunupakarn B; Chutasmit K; Saelow C; Runjarern R; Kaewmok W; Tripura R; Peto TJ; Yok S; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Lek D; Huy R; Dhorda M; Chotivanich K; Ashley EA; Mukaka M; Waithira N; Cheah PY; Maude RJ; Amato R; Pearson RD; Gonçalves S; Jacob CG; Hamilton WL; Fairhurst RM; Tarning J; Winterberg M; Kwiatkowski DP; Pukrittayakamee S; Hien TT; Day NP; Miotto O; White NJ; Dondorp AM
Lancet Infect Dis; 2019 Sep; 19(9):952-961. PubMed ID: 31345710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
